Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07384767 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing
A Phase 2 study, sponsored by University of California, Davis.
- Not yet
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT07384767: Clinical Trial Phase 2 study, sponsored by University of California, Davis.
NCT07384767 is a Phase 2 study that has not yet begun recruiting, run by University of California, Davis. The registered enrollment target is 220 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07384767, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, Davis.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the efficacy and safety of topical timolol 0.5% for secondary intention wound healing following 1) Mohs micrographic surgery, 2) standard surgical excision, OR 3) electrodesiccation and curettage (ED\&C). Please note that healing by secondary intention refers to when a wound heals naturally without surgical closure. To evaluate the efficacy of topical timolol 0.5%, 220 participants will be recruited. Participants will be placed into one of two groups: The treatment group or the control group. 1. The treatment group will receive a topical timolol 0.5% solution, which will be applied to their wound daily for 12 weeks. 2. The control group will receive standard care with the addition of hydrogel, which will also be applied to their wound daily for 12 weeks. During this 12-week period, both groups will be required to upload photos of their wound healing to their MyChart account at weeks 3, 6, 9, and 12. These photos will be reviewed by the investigator to assess wound healing. Re-epithelialization and earlier complete wound healing will be compared between both groups to determine the efficacy of topical timolol 0.5% solution compared to the standard of care.
Primary Outcome
The percent change in the area of surgical ulcers in patients using the study medication (treatment group) will be compared to those receiving standard care (placebo group).
Interventions
- DRUG Timolol 0.5% Ophthalmic Solution
- OTHER Hydrogel of placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What is known before NCT07384767 opens enrollment
NCT07384767 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher).
The record links to 0 conditions, and to 2 interventions - of which Timolol 0.5% Ophthalmic Solution is the first listed.
NCT07384767 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07384767 about?
NCT07384767 is a clinical study titled "Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing". The purpose of this research study is to evaluate the efficacy and safety of topical timolol 0.5% for secondary intention wound healing following 1) Mohs micrographic surgery, 2) standard surgical excision, OR 3) electrodesiccation and curettage (ED\&C). Please note that healing by secondary intenti...
What is the current status of trial NCT07384767?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2026-06-01. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07384767?
The interventions under investigation include: Timolol 0.5% Ophthalmic Solution (DRUG), Hydrogel of placebo (OTHER).
Who is sponsoring clinical trial NCT07384767?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07384767's enrollment target sits among peer trials
220 275th of 2000 higher than 1,718 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI